A protein phosphorylation-based assay for screening and monitoring of drugs modulating cyclic nucleotide pathways

Analytical Biochemistry

Volumn 407, Issue 2, 2010, Pages 261-269

  Geiger, Jörg ^a   Brandmann, Tobias ^a   Hubertus, Katharina ^a   Tjahjadi, Budy ^a   Schinzel, Reinhard ^b   Walter, Ulrich ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Vasopharm GmbH   (Germany)

Author keywords

CAMP; CAMP dependent protein kinase; CGMP; CGMP dependent protein kinase; Nitric oxide donors; Phosphodiesterase inhibitors; Prostaglandins; VASP

Indexed keywords

DIAGNOSIS; DISEASES; DRUG PRODUCTS; ENZYMES; ESTERS; NITRIC OXIDE; PHOSPHORYLATION;

CAMP; CGMP; NITRIC OXIDE DONOR; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; PROTEIN KINASE; VASP;

NUCLEOTIDES;

BIOLOGICAL MARKER; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE DEPENDENT PROTEIN KINASE; ENZYME INHIBITOR; PHOSPHODIESTERASE INHIBITOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ASSAY; EX VIVO STUDY; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCREENING TEST; THROMBOCYTE;

EID: 77957221052     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.08.006     Document Type: Article

References (42)

1. Walter U., Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood cells. Handb. Exp. Pharmacol. 2009, 191:533-548.
2. Boerriger G., Lapp H., Burnett J.C. Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb. Exp. Pharmacol. 2009, 191:485-506.
3. Sands W.A., Palmer T.M. Regulating gene transcription in response to cyclic AMP elevation. Cell. Signal. 2008, 20:460-466.
4. Naviglio S., Caraglia M., Abbruzzese A., Chiosi E., Di Gesto D., Marra M., Romano M., Sorrentino A., Sorvillo L., Spina A., Illiano G. Protein kinase A as a biological target in cancer therapy. Expert Opin. Ther. Targets 2009, 13:83-92.
5. Burton K.A., McKnight G.S. PKA, germ cells, and fertility. Physiology 2007, 22:40-46.
6. McPhee I., Gibson L.C., Kewney J., Darroch C., Stevens P.A., Spinks D., Cooreman A., MacKenzie S.J. Cyclic nucleotide signalling: a molecular approach to drug discovery for Alzheimer's disease. Biochem. Soc. Trans. 2005, 33:1330-1332.
7. Ghofrani H.A., Grimminger F. Modulating cGMP to treat lung diseases. Handb. Exp. Pharmacol. 2009, 191:469-483.
8. Reaume C.J., Sokolowski M.B. CGMP-dependent protein kinase as a modifier of behaviour. Handb. Exp. Pharmacol. 2009, 191:423-443.
9. Jackson E.B., Mukhopadhyay S., Tulis D.A. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system-from benchtop to bedside. Curr. Vasc. Pharmacol. 2007, 5:1-14.
10. Skålhegg B.S., Funderud A., Henanger H.H., Hafte T.T., Larsen A.C., Kvissel A.K., Eikvar S., Ørstavik S. Protein kinase A (PKA): a potential target for therapeutic intervention of dysfunctional immune cells. Curr. Drug Targets 2005, 6:655-664.
11. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58:488-520.
12. Burnett A.L. Phosphodiesterase 5 mechanisms and therapeutic applications. Am. J. Cardiol. 2005, 96:29M-31M.
13. Thompson P.E., Manganiello V., Degerman E. Re-discovering PDE3 inhibitors: new opportunities for a long neglected target. Curr. Top. Med. Chem. 2007, 7:421-436.
14. Kleppisch T. Phosphodiesterases in the central nervous system. Handb. Exp. Pharmacol. 2009, 191:71-92.
15. Schwede F., Maronde E., Genieser H.G., Jastorff B. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol. Ther. 2000, 87:199-226.
16. Taylor S.S., Kim C., Cheng C.Y., Brown S.H., Wu J., Kannan N. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim. Biophys. Acta 2008, 1784:16-26.
17. Francis S.H., Corbin J.D. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit. Rev. Clin. Lab. Sci. 1999, 36:275-328.
18. Lohmann S.M., Walter U. Tracking functions of cGMP-dependent protein kinases (cGK). Front. Biosci. 2005, 10:1313-1328.
19. Walter U., Eigenthaler M., Geiger J., Reinhard M. Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets. Adv. Exp. Med. Biol. 1993, 344:237-249.
20. Reinhard M., Jarchau T., Walter U. Actin-based motility: stop and go with Ena/VASP proteins. Trends Biochem. Sci. 2001, 26:243-249.
21. Horstrup K., Jablonka B., Hönig-Liedl P., Just M., Kochsiek K., Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur. J. Biochem. 1994, 225:21-27.
22. Lindsay S.L., Ramsey S., Aitchison M., Renné T., Evans T.J. Modulation of lamellipodial structure and dynamics by NO-dependent phosphorylation of VASP Ser239. J. Cell Sci. 2007, 120:3011-3021.
23. Smolenski A., Bachmann C., Reinhard K., Hönig-Liedl P., Jarchau T., Hoschuetzky H., Walter U. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J. Biol. Chem. 1998, 273:20029-20035.
24. Schwarz U.R., Walter U., Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem. Pharmacol. 2001, 62:1153-1161.
25. Yamamoto H., Takahashi K., Watanabe H., Yoshikawa Y., Shirakawa R., Higashi T., Kawato M., Ikeda T., Tabuchi A., Morimoto T., Kita T., Horiuchi H. Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. Circ. J. 2008, 72:1844-1851.
26. Aktas B., Utz A., Hönig-Liedl P., Walter U., Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003, 34:764-769.
27. Russo I., Del Mese P., Doronzo G., Mattiello L., Viretto M., Bosia A., Anfossi G., Trovati M. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress. Endocrinology 2008, 149:1480-1489.
28. Deguchi A., Soh J.W., Li H., Pamukcu R., Thompson W.J., Weinstein I.B. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol. Cancer Ther. 2002, 1:803-809.
29. van Werkum J.W., van der Stelt C.A., Seesing T.H., ten Berg J.M., Hackeng C.M. The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J. Thromb. Haemost. 2007, 5:881-883.
30. Geiger J., Teichmann L., Grossmann R., Aktas B., Steigerwald U., Walter U., Schinzel R. Monitoring of clopidogrel action: comparison of methods. Clin. Chem. 2005, 51:957-965.
31. Reinhard M., Zumbrunn J., Jaquemar D., Kuhn M., Walter U., Trueb B. An α-actinin binding site of zyxin is essential for subcellular zyxin localization and α-actinin recruitment. J. Biol. Chem. 1999, 274:13410-13418.
32. Drees B., Friederich E., Fradelizi J., Louvard D., Beckerle M.C., Golsteyn R.M. Characterization of the interaction between zyxin and members of the Ena/vasodilator-stimulated phosphoprotein family of proteins. J. Biol. Chem. 2000, 275:22503-22511.
33. Li B., Zhuang L., Trueb B. Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1. J. Biol. Chem. 2004, 279:20401-20410.
34. Eigenthaler M., Nolte C., Halbrügge M., Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases, and one of their major substrates in human platelets: estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur. J. Biochem. 1992, 205:471-481.
35. Manallack D.T., Hughes R.A., Thompson P.E. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J. Med. Chem. 2005, 48:3449-3462.
36. Wang J., Liu X.J. Monitoring protein kinase A activities using expressed substrate in live cells. Methods Mol. Biol. 2006, 322:425-433.
37. Herget S., Lohse M.J., Nikolaev V.O. Real-time monitoring of phosphodiesterase inhibition in intact cells. Cell. Signal. 2008, 20:1423-1431.
38. Dunkern T.R., Hatzelmann A. The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3, and 5. Cell. Signal. 2005, 17:331-339.
39. Blindt R., Stellbrink K., de Taeye A., Müller R., Kiefer P., Yagmur E., Weber C., Kelm M., Hoffmann R. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb. Haemost. 2007, 98:1329-1334.
40. Cayla G., Macia J.C., Rabesandratana H., Roubille F., Gervasoni R., Pasquié J.L., Barbotte E., Schved J.F., Leclercq F. Flow cytometric assessment of vasodilator-stimulated phosphoprotein: prognostic value of recurrent cardiovascular events after acute coronary syndromes. Arch. Cardiovasc. Dis. 2008, 101:743-751.
41. Michelson A.D., Frelinger A.L., Braunwald F., Downey W.E., Angiolillo D.J., Xenopoulos N.P., Jakubowski J.A., Li Y., Murphy S.A., Qin J., McCabe C.H., Antman E.M., Wiviott S.D. TRITON-TIMI 38 investigators, pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J. 2009, 30:1753-1763.
42. Aleil B., Meyer N., Cazenave J.P., Mossard J.M., Gachet C. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb. Haemost. 2005, 94:886-887.